JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 4
DOI:10.33266/1024-6177-2025-70-4-102-105
E.V. Efanova1, 2, Zh.A. Startseva3, S.A. Fursov1, 2, A.L. Chernyshova1, 4,
O.A. Tkachuk1, 2
Features of Radiation Reactions in Patients with Prostate Cancer
with Metabolic Syndrome on the Background of Thermoradiotherapy
1 Novosibirsk State Medical University, Novosibirsk, Russia
2 Novosibirsk Regional Clinical Oncological Dispensary, Novosibirsk, Russia
3 Cancer Research Institute of Tomsk National Research Medical Center, Tomsk. Russia
4 E.N. Meshalkin National Medical Research Center, Novosibirsk, Russia
Contact person: Ekaterina V. Efanova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ANNOTATION
Background: Prostate cancer (PC) is one of the most common cancers in men. According to the statistics of the Russian Federation for 2023, prostate cancer ranks 1st among malignant neoplasms in men (19.1 %) and 3rd (8.3 %) in the structure of mortality from malignant neoplasms in the male population. One of the main methods of treating prostate cancer is remote radiation therapy, with a combination of radiotherapy and local hyperthermia, the term thermoradotherapy is used. There has been a steady increase in patients with metabolic syndrome (MS) among prostate cancer patients. Given the complex hormonal and metabolic changes in MS, it is currently believed that this syndrome is a potential risk factor for an unfavorable prognosis in the treatment of prostate cancer.
Purpose: to evaluate the effect of metabolic syndrome in patients with prostate malignancy on the frequency and severity of adverse events during thermoradotherapy.
Material and methods: This non-randomized comparative study involved 60 patients diagnosed with prostate cancer (adenocarcinoma) T3-T4N0M0 who received remote radiation therapy using volume modulated therapy (VMAT) with irradiation of the prostate gland, seminal vesicles, and pelvic lymph nodes to a total focal dose (SOD) of 80/80/50 Gy in the mode 5 times a week, 28 sessions, on Electa linear electron accelerators Versa HD (Great Britain), photon beam of 6 Mev energy with local hyperthermia radio modification on a Celsius TCS device (Germany) according to the scheme: 2 times a week, 8–10 procedures in total 2 hours before radiation therapy, heating duration 40–60 minutes at a temperature of 40–42 °C. The study group included 30 people who received thermoradotherapy and were diagnosed with metabolic syndrome (according to the criteria of the IDF in 2009) before starting treatment. The control group consisted of 30 patients undergoing thermoradotherapy without a history of metabolic syndrome.
Results and discussion: Analysis of these patient groups shows that in the category of prostate cancer patients with metabolic syndrome, compared with the control group, more pronounced radiation reactions prevail, such as radioepitheliitis on the skin at the site of irradiation and nocturia. Metabolic changes cause disorders of lymphatic and circulatory microcirculation, skin repair processes; abdominal obesity leads to increased intra-abdominal pressure, which increases the frequency of urination at night.
Conclusion: Prostate cancer patients with metabolic syndrome receiving thermoradotherapy require great attention from doctors due to the increased risk of developing severe radiation reactions. In this regard, further research in this area is necessary, which makes an unconditional contribution to improving the effectiveness of treatment in this category of patients.
Keywords: prostate cancer, radiation therapy, local hyperthermia, thermoradotherapy, metabolic syndrome, radiation reactions
For citation: Efanova EV, Startseva ZhA, Fursov SA, Chernyshova AL, Tkachuk OA. Features of Radiation Reactions in Patients with Prostate Cancer with Metabolic Syndrome on the Background of Thermoradiotherapy. Medical Radiology and Radiation Safety. 2025;70(4):102–105. (In Russian). DOI:10.33266/1024-6177-2025-70-4-102-105
References
1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennyye Novoobrazovaniya v Rossii v 2023 Godu (Zabolevayemost’ i Smertnost’) = Malignant Neoplasms in Russia in 2023 (Morbidity and Mortality). Moscow, Moskovskiy Nauchno-Issledovatel’skiy Onkologicheskiy Institut Imeni P.A.Gertsena Publ., 2023. 276 p. (In Russ.).
2. Kipriyanov Ye.A. Gipertermiya kak Komponent Kompleksnogo Lecheniya Bol’nykh Rakom Predstatel’noy Zhelezy = Hyperthermia as a Component of Complex Treatment of Patients with Prostate Cancer. Doctor’s Thesis (Med.). Moscow Publ., 2009. 154 p. (In Russ.).
3. Nosov D.A., Volkova M.I., Gladkov O.A., Karabina Ye.V., Krylov V.V., Matveyev V.B., et al. Practical Recommendations for drug Treatment of Prostate Cancer. Prakticheskiye Rekomendatsii RUSSCO = Practical Recommendations RUSSCO. 2023;13:640-660 (In Russ.). doi: 10.18027/2224-5057-2021-11-3s2-33 (In Russ.).
4. Peshkov M.N., Peshkova G.P., Reshetov I.V. Metabolic Changes in Patients with Prostate Cancer during Androgen Deprivation Therapy. Sakharnyy Diabet = Diabetes Mellitus. 2020;23;2:192-200 (In Russ.).
5. Moon S., Chung H.S., Yu J.M., Ko K.J., Choi D.K., Kwon O., Lee Y.G., Cho S.T. The Association Between Obesity and the Nocturia in the U.S. Population. Int Neurourol J. 2019 Jun;23;2:169-176.
6. Knights A.J., Funnell A.P., Pearson R.C., et al. Adipokines and Insulin Action: a Sensitive Issue. Adipocyte. 2014;3;2:88-96.
7. Losano G., Folino A., Rastaldo R. Role of Three Adipokines in Metabolic Syndrome. Pol Arch Med Wewn. 2016;126;4:219-221.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. E.V. Efanova – study design, patient selection according to inclusion criteria, patient management, filling out primary documentation, writing the manuscript; Z.A. Startseva – general management of the study, proofreading the article; S.A. Fursov – general management of the study, proofreading the article; A.L. Chernyshova –proofreading the article; O.A. Tkachuk – study design, proofreading the article. All authors read and approved the final version before publication.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.03.2025. Accepted for publication: 25.04.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 4
DOI:10.33266/1024-6177-2025-70-4-106-110
A.V. Muravleva1, 3, V.I. Chernov1, 2, V.E. Goldberg1, E.A. Shamsimukhametova1,
R.V. Zelchan1, 2, A.A. Medvedeva1, 2, O.D. Bragina1, 2, N.O. Popova1,
V.V. Vysotskaya1, A.N. Rybina1, A.V. Goldberg1
SPECT/CT with 99mTc-PSMA in the Staging and Diagnosis of Hodgkin Lymphoma
1 Tomsk National Research Medical Center, Tomsk, Russia
2 National Research Tomsk Polytechnic University, Tomsk, Russia
3 Siberian State Medical University, Tomsk, Russia
Contact person: A.V. Muravleva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpose: Demonstrate the possibility of using 99mTc-PSMA SPECT/CT to visualize Hodgkin’s lymphoma at the diagnostic stage, as well as during therapy.
Material and methods: The patient diagnosed with Hodgkin’s lymphoma underwent standard studies – computed tomography with intravenous contrast, as well as PET/CT with 18F-FDG. Additionally, 99mTc-PSMA SPECT/CT was performed.
Results: A clinical case of Hodgkin’s lymphoma with mediastinal lesions in a young patient is described. The possibility of modern nuclear medicine methods in the diagnosis of Hodgkin’s lymphoma is demonstrated. SPECT/CT with 99mTc-PSMA was performed as an alternative diagnostic method when it is impossible to perform PET/CT with 18F-FDG at the stage of specific treatment.
Conclusion: The article presents a clinical case of Hodgkin’s lymphoma with mediastinal involvement in a young patient. The capabilities of SPECT/CT with 99mTc-PSMA for visualization of mediastinal lesions was demonstrated.
Keywords: Hodgkin’s lymphoma, prostate-specific membrane antigen, SPECT/CT, 99mTc-PSMA
For citation: Muravleva AV, Chernov VI, Goldberg VE, Shamsimukhametova EA, Zelchan RV, Medvedeva AA, Bragina OD, Popova NO, Vysotskaya VV, Rybina AN, Goldberg AV. SPECT/CT with 99mTc-PSMA in the Staging and Diagnosis of Hodgkin Lymphoma. Medical Radiology and Radiation Safety. 2025;70(4):106–110. (In Russian). DOI:10.33266/1024-6177-2025-70-4-106-110
References
1. Rossiyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Zlokachestvennykh Limfoproliferativnykh Zabolevaniy = Russian Clinical Guidelines for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases. Ed. I.V.Poddubnaya, V.G.Savchenko. Samara Publ., 2018. 470 p. (In Russ.).
2. Salas Fragomeni R.A., Amir T., Sheikhbahaei S., Harvey S.C., Javadi M.S., Solnes L.B., et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018;59;6:871-7. doi: 10.2967/jnumed.117.203570.
3. Al-Ahmadie H.A., Olgac S., Gregor P.D., Tickoo S.K., Fine S.W., Kondagunta G.V., et al. Expression of Prostate-Specific Membrane Antigen in Renal Cortical Tumors. Mod Pathol. 2008;21;6:727-32. doi: 10.1038/modpathol.2008.42.
4. Wang J.H., Kiess A.P. PSMA-Targeted Therapy for Non-Prostate Cancers. Front Oncol. 2023 Aug 14;13:1220586. doi: 10.3389/fonc.2023.1220586. PMID: 37645427. PMCID: PMC10461313.
5. Chernov V.I., Dudnikova Ye.A., Gol’dberg V.Ye., Kravchuk T.L., Danilova A.V., Zel’chan R.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D., Popova N.O., Gol’dberg A.V. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphoproliferative Diseases. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2018;63;6:41-50 (In Russ.).
6. Barrington S.F., Mikhaeel N.G., Kostakoglu L., et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58. doi: 10.1200/JCO.2013.53.5229.
7. Cheson B.D., Fisher R.I., Barrington S.F., et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: the Lugano Classification. J Clin Oncol. 2014;32:3059-68. doi: 10.1200/JCO.2013.54.8800.
8. Dreyling M., Thieblemont C., Gallamini A., et al. ESMO Consensus Conferences: Guidelines on Malignant Lymphoma. Part 2: Marginal Zone Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma. Ann Oncol. 2013;24:857–77. doi: 10.1093/annonc/mds643.
9. Boellaard R., Delgado-Bolton R., Oyen W.J.G., et al. FDG PET/CT: EANM Procedure Guidelines for Tumour Imaging: Version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-354.
10. Zeltchan R., Medvedeva A., Sinilkin I., et al. Experimental Study of Radiopharmaceuticals Based on Technetium-99m Labeled Derivative of Glucose for Tumor Diagnosis. VIII International Scientific Conference Issues of Physics and Technology in Science, Industry and Medicine. Tomsk, 1–3 June, 2016. IOP Conference Series: Materials Science and Engineering. 2016;135:012054. doi. 10.1088/1757-899X/135/1/012054.
11. Zel’chan R.V., Medvedeva A.A., Sinilkin I.G., et al. Study of the Functional Suitability of the Tumorotropic Radiopharmaceutical 99mTc-1-thio-D-glucose in an Experiment. Molekulyarnaya Meditsina = Molecular Medicine. 2018;16;2:54-57 (In Russ.). doi: 10.29296/24999490-201803-11
12. Chernov V.I., Medvedeva A.A., Sinilkin I.G., et al. Development of Radiopharmaceuticals for Radionuclide Diagnostics in Oncology. Meditsinskaya Vizualizatsiya = Medical Visualization. 2016;2:63-66 (In Russ.).
13. Chernov V.I., Dudnikova E.A., Zelchan R.V., et al. The First Experience of Using 99mTc-1-Thio-d-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Siberian Oncology Journal. 2018;17;4:81-87. doi: 10.21294/1814-4861-2018-17-4-81-87.
14. Dudnikova Ye.A., Chernov V.I., Muravleva A.V., et al. Metabolic Single-Photon Emission Computed Tomography with a new Radiopharmaceutical Drug «99mTc-1-thio-D-glucose» in the Diagnosis and Monitoring of Isolated Breast Lymphoma (Clinical Observation). Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2020;19;5:145-153 (In Russ.). doi: 10.21294/1814-4861-2020-19-5-145-153.
15. Muravleva A.V., Chernov V.I., Dudnikova Ye.A., et al. Metabolic Single-Photon Emission Computed Tomography with “99mTc-1-thio-d-glucose” - New Possibilities for Staging Hodgkin’s Lymphoma. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiation Diagnostics. 2021;11;3:171-177 (In Russ.). doi: 10.21569/2222-7415-2021-11-3-171-177.
16. Chernov V., Dudnikova E., Zelchan R., Medvedeva A., Rybina A., Bragina O., Goldberg V., Muravleva A., Sörensen J., Tolmachev V. Phase I Clinical Trial Using [99mTc]Tc-1-Thio-D-Glucose for Diagnosis of Lymphoma Patients. Pharmaceutics. 2022;14:1274.
17. Tolmachev V.M., Chernov V.I., Deyev S.M. Targeted Nuclear Medicine. See and Destroy. Russ Chem Rev. 2022;91:RCR5034 (In Russ.). doi: 10.1070/RCR5034.
18. Chernov V.I. Innovative Radiopharmaceuticals in Diagnostics and Radionuclide Therapy of Malignant Neoplasms. Vestnik Rossiyskoy Akademii Nauk = Bulletin of the Russian Academy of Sciences. 2024;94;1:66-79 (In Russ.). doi: 10.31857/S0869587324010088.
19. Lishmanov Yu.B., Chernov V.I., Krivonogov N.G., Glukhov G.G., Maslova L.V. Perfusion Scintigraphy of the Myocardium with 199Tl-Chloride in the Experiment. Meditsinskaya Radiologiya = Medical Radiology. 1988;33;3:13-16 (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out with the financial support of the transport hub development program «Priority 2030» (Priority-2030-IZ-024-
202-2024).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.03.2025. Accepted for publication: 25.04.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 3
DOI:10.33266/1024-6177-2025-70-3-11-15
S.A. Korneva1, A.K. Chigasova1, 2, 3, A.A. Osipov2, M.A. Ignatov1, 2,
N.Yu. Vorobyova1, 2, V.O. Saburov4, E.I. Kazakov4, S.N. Koryakin4,
Yu.A. Fedotov1, 2, A.Yu. Bushmanov1, A.N. Osipov1, 2
Post-Irradiation Changes in the Number of γH2ax and patm Protein Foci in Human Mesenchymal Stem Cells Irradiated with 14.1 MeV Neutrons
1 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
2 N.N. Semenov Federal Research Center for Chemical Physics, Moscow, Russia
3 Institute of Biochemical Physics, Moscow, Russia
4 A.F. Tsyb Medical Radiological Research Center, Obninsk, Russia
Contact person: A.N. Osipov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpose: Comparative analysis of dose-response dependences and kinetics of post-radiation changes in the number of γH2AX and pATM protein foci in human mesenchymal stem cells (MSCs) exposed to 14.1 MeV neutrons and cobalt-60 gamma-radiation.
Material and methods: The study used a primary culture of human MSCs obtained from the collection of BioloT LLC (Russia). The cells were irradiated using a neutron generator NG-14 (VNIIA, Russia), which provided neutron fluxes with an energy of 14.1 MeV, and a gamma-therapeutic device ROKUS-AM (JSC Ravenstvo, Russia; cobalt-60, dose rate 0.5 Gy/min) at doses of 0.1, 0.25 and 0.5 Gy. For quantitative assessment of γH2AX and pATM foci, immunocytochemical staining was done using antibodies to γH2AX and pATM, respectively. Statistical significance was assessed using analysis of variance (ANOVA).
Results: It was shown that the kinetics of post-radiation changes in the number of γH2AX foci in cells irradiated with neutrons is slower than after gamma irradiation. 24 h after irradiation with neutrons, ~ 62 % of γH2AX foci and ~ 52 % of pATM foci were recorded from their number 0.5 h after irradiation. These values were statistically significantly (p < 0.001) higher than the proportions of residual foci calculated after exposure to gamma-radiation: ~ 16 % and 6 %, respectively. The results obtained indicate that the proportion of complex, difficult-to-repair DNA damage in cells irradiated with neutrons is significantly higher than with gamma-radiation.
Keywords: mesenchymal stem cells, fast neutrons, gamma-radiation, γH2AX, рATM, DNA damage, DNA repair
For citation: Korneva SA, Chigasova AK, Osipov AA, Ignatov MA, Vorobyova NYu, Saburov VO, Kazakov EI, Koryakin SN, Fedotov YuA, Bushmanov AYu, Osipov AN. Post-Irradiation Changes in the Number of γH2AX and patm Protein Foci in Human Mesenchymal Stem Cells Irradiated with 14.1 MeV Neutrons. Medical Radiology and Radiation Safety. 2025;70(3):11–15. (In Russian). DOI:10.33266/1024-6177-2025-70-3-11-15
References
1. Nickoloff J.A., Sharma N., Allen C.P., Taylor L., Allen S.J., Jaiswal A.S., et al. Roles of Homologous Recombination in Response to Ionizing Radiation-Induced DNA Damage. Int J Radiat Biol. 2023;99;6:903-14. doi: 10.1080/09553002.2021.1956001.
2. Mladenov E., Mladenova V., Stuschke M., Iliakis G. New Facets of DNA Double Strand Break Repair: Radiation Dose as Key Determinant of HR Versus c-NHEJ Engagement. International Journal of Molecular Sciences. 2023;24;19:49-56. doi: 10.3390/ijms241914956.
3. Belov O., Chigasova A., Pustovalova M., Osipov A., Eremin P., Vorobyeva N., et al. Dose-Dependent Shift in Relative Contribution of Homologous Recombination to DNA Repair after Low-LET Ionizing Radiation Exposure: Empirical Evidence and Numerical Simulation. Current Issues in Molecular Biology. 2023;45;9:7352-73. doi: 10.3390/cimb45090465.
4. Krenning L., van den Berg J., Medema R.H. Life or Death after a Break: what Determines the Choice? Mol Cell. 2019;76;2:346-58. doi: 10.1016/j.molcel.2019.08.023.
5. Torgovnick A., Schumacher B. DNA Repair Mechanisms in Cancer Development and Therapy. Front Genet. 2015;6:157. doi: 10.3389/fgene.2015.00157.
6. White R.R., Vijg J. Do DNA Double-Strand Breaks Drive Aging? Mol Cell. 2016;63;5:729-38. doi: 10.1016/j.molcel.2016.08.004.
7. Jiang Y. Contribution of Microhomology to Genome Instability: Connection between DNA Repair and Replication Stress. International Journal of Molecular Sciences. 2022;23;21:129-37. doi: 10.3390/ijms232112937.
8. Sishc B.J., Davis A.J. The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers (Basel). 2017;9;7:81. doi: 10.3390/cancers9070081.
9. Osipov A., Chigasova A., Yashkina E., Ignatov M., Vorobyeva N., Zyuzikov N., et al. Early and Late Effects of Low-Dose X-ray Exposure in Human Fibroblasts: DNA Repair Foci, Proliferation, Autophagy, and Senescence. International Journal of Molecular Sciences. 2024;25;15:8253. doi: 10.3390/ijms25158253.
10. Barbieri S., Babini G., Morini J., Friedland W., Buonanno M., Grilj V., et al. Predicting DNA Damage Foci and their Experimental Readout with 2D Microscopy: a Unified Approach Applied to Photon and Neutron Exposures. Sci Rep. 2019;9;1:14019. doi: 10.1038/s41598-019-50408-5.
11. Rothkamm K., Barnard S., Moquet J., Ellender M., Rana Z., Burdak-Rothkamm S. DNA Damage Foci: Meaning and Significance. Environ Mol Mutagen. 2015;56;6:491-504. doi: 10.1002/em.21944.
12. Penninckx S., Pariset E., Cekanaviciute E., Costes S.V. Quantification of Radiation-Induced DNA Double Strand Break Repair Foci to Evaluate and Predict Biological Responses to Ionizing Radiation. NAR Cancer. 2021;3;4:zcab046. doi: 10.1093/narcan/zcab046.
13. Belyaev I.Y. Radiation-Induced DNA Repair Foci: Spatio-Temporal Aspects of Formation, Application for Assessment of Radiosensitivity and Biological Dosimetry. Mutat Res. 2010;704;1-3:132-41. doi: 10.1016/j.mrrev.2010.01.011.
14. Wanotayan R., Chousangsuntorn K., Petisiwaveth P., Anuttra T., Lertchanyaphan W., Jaikuna T., et al. A Deep Learning Model (FociRad) for Automated Detection of Gamma-H2AX Foci and Radiation Dose Estimation. Sci Rep. 2022;12;1:5527. doi: 10.1038/s41598-022-09180-2.
15. Vorobyeva N.Y., Osipov A.A., Chigasova A.K., Yashkina E.I., Osipov A.N. Changes in the Number of Residual γH2AX Foci in Ki-67-Positive and Ki-67-Negative Human Fibroblasts Irradiated with X-Rays in Doses of 2-10 Gy. Bulletin of Experimental Biology and Medicine. 2023;175;4:450-3. doi: 10.1007/s10517-023-05883-2.
16. Vorobyeva N.Y., Astrelina T.A., Yashkina E.I., Chigasova A.K., Osipov A.A., Usupzhanova D.Y., et al. Effect of a Humic-Fulvic Acid Preparation on the Quantitative Yield of Residual γH2AX Foci and Proliferative Activity in Irradiated Human Mesenchymal Stromal Cells. Medical Radiology and Radiation Safety. 2023;68;2:11-5. doi: 10.33266/1024-6177-2023-68-2-11-15.
17. Falaschi A., Chiaramonte A., Testi S., Scarpato R. Dual Immunofluorescence of gammaH2AX and 53BP1 in Human Peripheral Lymphocytes. J Vis Exp. 2023;197:654-72. doi: 10.3791/65472.
18. Vorobyeva N.Y., Osipov A.A., Chigasova A.K., Pustovalova M.V., Kabanov D.I., Barchukov V.G., et al. Comparative Study of Changes in the γh2ax and 53bp1 Foci Number in Human Mesenchymal Stromale Cells Incubated with 3H-thymidine or Tritiated Water. Medical Radiology and Radiation Safety. 2023;68;3:5-10. doi: 10.33266/1024-6177-2023-68-3-5-10.
19. Slonina D., Kowalczyk A., Janecka-Widla A., Kabat D., Szatkowski W., Biesaga B. Low-Dose Hypersensitive Response for Residual pATM and gammaH2AX Foci in Normal Fibroblasts of Cancer Patients. Int J Radiat Oncol Biol Phys. 2018;100;3:756-66. doi: 10.1016/j.ijrobp.2017.10.054.
20. Chigasova A.K., Pustovalova M.V., Osipov A.A., Korneva S.A., Eremin P.S., Yashkina E.I., et al. Post-Radiation Changes in The Number of Phosphorylated H2ax and Atm Protein Foci in Low Dose X-Ray Irradiated Human Mesenchymal Stem Cells. Medical Radiology and Radiation Safety. 2024;69;1:15-9. doi: 10.33266/1024-6177-2024-69-1-15-19.
21. Valente D., Gentileschi M.P., Guerrisi A., Bruzzaniti V., Morrone A., Soddu S., et al. Factors to Consider for the Correct Use of gammaH2AX in the Evaluation of DNA Double-Strand Breaks Damage Caused by Ionizing Radiation. Cancers (Basel). 2022;14;24:6204. doi: 10.3390/cancers14246204.
22. Shibata A., Jeggo P.A. ATM’s Role in the Repair of DNA Double-Strand Breaks. Genes (Basel). 2021;12;9:1370. doi: 10.3390/genes12091370.
23. Osipov A.N., Pustovalova M., Grekhova A., Eremin P., Vorobyova N., Pulin A., et al. Low Doses of X-Rays Induce Prolonged and ATM-Independent Persistence of GammaH2AX Foci in Human Gingival Mesenchymal Stem Cells. Oncotarget. 2015;6;29:27275-87. doi: 10.18632/oncotarget.4739.
24. Ozerov I.V., Osipov A.N. Kinetic Model of DNA Double-Strand Break Repair in Primary Human Fibroblasts Exposed to Low-LET Irradiation with Various Dose Rates. Computer Research and Modeling. 2015;7;1:159-76. doi: 10.20537/2076-7633-2015-7-1-159-176.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The research was carried out within the framework of the state assignment of the Ministry of Science and Higher Education of the Russian Federation (No. 1023112000035-8, code “Cosmos-DNA”).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.02.2025. Accepted for publication: 25.03.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 3
DOI:10.33266/1024-6177-2025-70-3-5-10
Yu.B. Deshevoi, V.G. Lebedev, T.A. Nasonova, O.A. Dobrynina,
V.A. Brunchukov, I.V. Kobzeva, T.A. Astrelina, A.S. Samoylov
Study of the Efficacy of Cell Therapy for Severe Local Radiation Injuries in the Use of Drugs Affecting the State of Irradiated Tissues Before Cell Transplantation
A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Yu.B. Deshevoi, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To study the possibility of enhancing the therapeutic efficacy of multipotent mesenchymal stromal cells (MMSC) or stromal vascular fraction (SVF) cells in the treatment of severe local radiation injuries under the conditions of the use of pharmacological drugs, the use of which before and after cell transplantation can improve the condition of the irradiated tissue and thereby create favorable conditions for engraftment and functioning of the injected cells.
Material and methods: The work was carried out on male rats of the Wistar–Kyoto inbred line weighing 260–280 g. The animals were locally irradiated in the iliolumbar region of the back on an X-ray machine LNK-268 (RAP 100–10) at a dose of 110 Gy (voltage on the tube 30 kV, current 6.1 mA, Al filter with a thickness of 0.1 mm), at a dose rate of 20.0 Gy/min. The area of the irradiation field was 8.5 cm2. The severity of radiation damage to the skin and the effects of treatment were assessed in dynamics by clinical manifestations and using planimetry. After exposure to radiation, rats developed radiation ulcers of the skin that did not heal for a long time (up to 3–4 months). Cell and drug therapy were carried out in different periods after irradiation: from the 28th to the 49th or from the 35th to the 56th day. As drugs affecting the condition of the affected tissues surrounding the formed radiation ulcer, a complex antibiotic levotetrasulfin forte and drugs that affect the microcirculation and trophism of irradiated tissues – pentoxifylline and detralex were used. For cell therapy, syngeneous MMSC or SVF cells were used. In the cell therapy setting, the drugs were administered for one week before the first cell transplant, one week between the first and second transplantation, and one week after the second cell transplant.
Results and Conclusion: It was shown that the administration of drugs or the use of cell therapy when used separately stimulated the healing of radiation ulcers. Moreover, the therapeutic effect of cell therapy is more pronounced than with the use of drugs. However, in combination with drug and cell therapy, no enhancing effect of pharmacological agents on the therapeutic efficacy of transplantation of MMSC or SVF cells of adipose tissue was noted. Thus, these experiments showed the possibility of successful use of a complex antibiotic in combination with drugs that improve blood supply and trophism of irradiated tissues in the treatment of severe local radiation injuries and the inability of drug therapy under these conditions to enhance the therapeutic effectiveness of cell therapy.
Keywords: radiation ulcer, transplantation of cells, stromal-vascular fraction of adipose tissue, multipotent mesenchymal stromal cells, drug therapy
For citation: Deshevoi YuB, Lebedev VG, Nasonova TA, Dobrynina OA, Brunchukov VA, Kobzeva IV, Astrelina TA, Samoylov AS. Study of the Efficacy of Cell Therapy for Severe Local Radiation Injuries in the Use of Drugs Affecting the State of Irradiated Tissues Before Cell Transplantation. Medical Radiology and Radiation Safety. 2025;70(3):5–10. (In Russian). DOI:10.33266/1024-6177-2025-70-3-5-10
References
1. Radiatsionnaya Meditsina = Radiation Medicine. A Guide for Medical Researchers and Healthcare Organizers. Ed. L.A.Il’in. Vol.2. Moscow, IzdAT Publ., 2001. 432 p. (In Russ.).
2. Nadezhina N.M, Galstyan I.A. Lecheniye Mestnykh Luchevykh Porazheniy = Treatment of Local Radiation Injuries. Ed. K.V.Kotenko, A.Yu.Bushmanov. Moscow, FMBTS im. A.I.Burnazyana FMBA Rossii Publ., 2013. 99 p. (In Russ.).
3. Isakson M., C.de Blacam, Whelan D., McArdle A., Glove A.J. Mesenchymal Stem Cells and Cutaneous Wound Healing: Current Evidence and Future Potential. Review Article. Hundawi Publishing Corporation. Stem Cells International (Internet). 2015. Article ID 831095. 12 p. doi: 10.1155/2015/831095.
4. Bourin P., Bunnell B.A., Casteilla L., Dominici M., Katz A.J., March K.L., Rendl H., Rubin J.P., Yoshimura K., Gimble J.M. Stromal Cells from the Adipose Tissue-Derived Stromal Vascular Fraction and Cultured Expanded Adipose Tissue-Derived Stromal/Stem Cells: a Joint Statement of the International Federation for Adipose Therapeutics and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15:641-648.
5. Francois S., Mouiseddine M., Mathieu N., Semont A., Monti P., Dudoignon N., Sache A., Boutarfa A., Thierry D., Gourmelion P., Chapel A. Human Mesenchymal Stem Cells Favour Healing of the Cutaneous Radiation Syndrome in a Xenogenic Transplant Model. Annals of Hematology. 2007;86;1:1–8.
6. Kotenko K.V., Yeremin I.I., Moroz B.B., Bushmanov A.YU., Nadezhina N.M., Galstyan I.A., Deshevoy YU.B., Lebedev V.G., Nasonova T.A., Dobrynina O.A., Lyrshchikova A.V. Cellular Technologies in the Treatment of Radiation Burns: the Experience of the A.I.Burnazyan Federal Medical Biophysical Center. Kletochnaya Transplantologiya i Tkanevaya Inzheneriya = Cell Transplantology and Tissue Engineering. 2012;2;7:97–102 (In Russ.).
7. Deshevoy Yu.B., Nasonova T.A., Dobrynina O.A., Deyev R.V., Lebedev V.G., Lyrshchikova A.V., Astrelina T.A., Moroz B.B. Experience of Using Syngeneic Multipotent Mesenchymal Stem Cells (MMSC) of Adipose Tissue for the Treatment of Severe Radiation-Induced Skin Lesions in an Experiment. Radiatsionnaya Biologiya. Radioekologiya = Radiation biology. Radioecology. 2020;1;60:26-33 (In Russ.).
8. Deshevoy Yu.B., Lebedev V.G., Nasonova T.A., Dobrynina O.A., Lyrshchikova A.V., Astrelina T.A., Moroz B.B. (In Russ.). Comparative Efficacy of Syngeneic Cultured Mesenchymal Stem Cells (MMSC) and Freshly Isolated Cells of the Stromal-Vascular Fraction (SVF) of Adipose Tissue in the Treatment of Severe Local Radiation Injuries in an Experiment. Radiatsionnaya Biologiya. Radioekologiya = Radiation biology. Radioecology. 2021;2;61:151-157 (In Russ.).
9. Brunchukov V.A., Astrelina T.A., Nikitina I.V., Kobzeva I.V., Suchkova Yu.B., Usupzhanova D.Yu., Rastorguyeva A.A., Karaseva T.V., Gordeyev A.V., Maksimova L.A., Naumova L.A., Lishchuk S.V., Dubova Ye.A., Pavlov K.A., Brumberg V.A., Makhova A.Ye., Lomonosova Ye.Ye., Dobrovol’skaya Ye.I., Bushmanov A.Yu., Samoylov A.S. Experimental Treatment of Local Radiation Injuries with Mesenchymal Stem Cells and their Conditioned Environment. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2020;1;65:5-12 (In Russ.).
10. Cassia Noronha N., Mizukami A., Calary-Oliveira C. Priming Approaches to Improve the Efficacy of Mesenchymal Stromal Cell-Based Therapies. Stem Cell Research & Therapy. 2019;10:131-143.
11. Anh Bui T.V., Hwang Ji., Lee J. Challenges and Limitations of Strategies to Promote Therapeutic Potential of Human Mesenchymal Stem Cell for Stem Cells-Based Cardiac Repair. Korean Circ. J. 2021;51;2:97-113.
12. Zhao Y., Wang M., Liang F., Li J. Recent Strategies for Enhancing the Therapeutic Efficacy of Stem Cells in Wound Healing. Stem Cell Research & Therapy. 2021;12:588-599.
13. Kotenko K.V., Moroz B.B., Nasonova T.A., Dobrynina O.A, Lipengol’ts A.D., Gimadova T.I., Deshevoy Yu.B., Lebedev V.G., Lyrshchikova A.V., Yeremin I.I. Experimental Model of Severe Local Radiation Skin Lesions After Exposure to X-Rays. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya = Pathological Physiology and Experimental Therapy. 2013;4:121–123 (In Russ.).
14. Kolev M., Donchev N., Borov M. Experimental Research on the Toxicity of Pharmapentoxifylline. Exp. Med. Morhpol. 1990;29;4:57-61.
15. Product Monograph. PrTRENTAL®.ATC Code: C04AD03. Sanofi-Aventis Canada Inc. Date of Revision: March 30, 2011. 21 p.
16. Man M.Q., Yang B., Elias P.M. Benefits of Hesperidin for Cutaneous Functions. Hindawi Evidence-Based Complementary and Alternative Medicine. 2019. Article ID 2676307. 19 p. doi: 10.1155/2019/2676307.
17. Gunik A.V., Parshin P.A., Vostroilova G.A. Toxicity Parameters of the Complex antimicRobial drug Levoterasulfin Forte. Proceedings of the International Scientific and Practical Conference Aktual’nyye Problemy Bolezney Molodnyaka v Sovremennykh Usloviyakh = Current Problems of Diseases of Young Animals in Modern Conditions, Voronezh, September 23-25, 2002. Voronezh Publ., 2002. P.11 (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.02.2025. Accepted for publication: 25.03.2025.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 3
DOI:10.33266/1024-6177-2025-70-3-16-21
V.P. Mamina
Protective Effect of Dimethylsulphoxide in Combination with Gluthathione and Cysteamine Against the Damaging Effect of Ionizing Radiation on Spermatogenesis
Institute of Plant and Animal Ecology, Ekaterinburg, Russia
Contact person: Vera Pavlovna Mamina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpose: Experimental assessment of the radioprotective effect of dimethylsulfoxide in combination with glutathione and cysteamine on spermatogenesis in BALB/c mice under acute γ-irradiation.
Material and мethods:A single external γ-irradiation of male mice at a dose of 6 Gy was carried out on an IGUR installation (137Cs, dose rate 0.85 Gy/min).The timing of death of mice was recorded within 1 month. Animals 20 minutes before irradiation received an intraperitoneal injection of a mixture of dimethyl sulfoxide (4.5 g/kg), reduced glutathione (500 mg/kg) and cysteamine (150 mg/kg).The disturbance of spermatogenesis and its correction with a mixture of radioprotectors was assessed by quantitative indicators of spermatogenic cells and the morphofunctional state of sperm.
Results: In mice, on the 8th day after irradiation, the number of spermatogonia decreases (6 % of the control), on the 24th day – the number of spermatocytes, spermatids and spermatozoa – to 3.5 %, 6 % and 4.5 % of the control, respectively. The mixture of radioprotectors contributed to an increase in the number of spermatogonia up to 33 %, spermatocytes – up to 7 %, spermatids – up to 25 %, spermatozoa – up to 27 %.The viability coefficient (QC) of spermatogenic cells decreases on the 8th day after irradiation from 11.6 in the control to 8.0, on the 16th day – to 7.0, on the 24th day – to 6.0, on 32 1st and 62nd days – up to 5.0. When using radioprotectors, QoL on the 8th day corresponded to 10.0 and in subsequent periods was kept within 9.0.The number of epididymal spermatozoa decreases on the 24th day after irradiation to 80 %, on the 32nd day – to 60%, on the 62nd day – to 45 %. The mixture of radioprotectors contributed to an increase in the number of sperm to 95 % and 60 %, respectively).The number of live sperm decreases on the 32nd and 62nd days after irradiation and amounts to 35 % and 18 %, respectively, when using radioprotectors – 45 % and 30 %, respectively. On the 24th, 32nd and 62nd days after irradiation, the number of sperm with an abnormal head increases by 2 times. Radioprotectors reduce the number of sperm with an abnormal head by 1.5 times.
Conclusion: The data obtained indicate the protective effect of this mixture of radioprotectors on spermatogenesis and its possible use for the correction of spermatogenesis disorders when exposed to ionizing radiation. The mixture of protectors provides protection for 95 % of mice, with 65 % death in irradiated controls.
Keywords: external acute γ-irradiation, spermatogenesis, spermatozoa, DMSO, glutathione, cysteamine, mice
For citation: Mamina VP. Protective Effect of Dimethylsulphoxide in Combination with Gluthathione and Cysteamine Against the Damaging Effect of Ionizing Radiation on Spermatogenesis. Medical Radiology and Radiation Safety. 2025;70(3):16–21. (In Russian). DOI:10.33266/1024-6177-2025-70-3-16-21
References
1.Agarwal A., Baskaran S., Parekh N., Cho C.L., Henkel R., Vij S., et al. Male Infertility. Lancet. 2021;397;10271:319–33. doi: 10.1016/S0140-6736(20)32667-2.
2.Kaplan M.A., Lepokhin N.P. Assessment of the State of Reproductive Function of Participants in the Chernobyl Accident 13-14 Years after the Radiation Disaster. Radiatsiya i Risk = Radiation and Risk. 2002;13:42-44 (In Russ.).
3.Farhood B., Mortezaee K., Haghi-Aminjan H., Khanlarkhani N., Salehi E. A Systematic Review of Radiation-Induced Testicular Toxicities Following Radiotherapy for Prostate Cancer. Cell Physiol. 2019;234;9:14828-14837. doi: 10.1002/jcp.28283. PMID: 30740683.
4.Vereshchako G.G., Khodosovskaya A.M., Fedosenko O.L. Radiatsionnoye Porazheniye i Puti Vosstanovleniya Reproduktivnoy Sistemy Samtsov Mlekopitayushchikh = Radiation Damage and Ways of Restoring the Reproductive System of Male Mammals. Minsk, Belaruskaya Navuka Publ., 2018. 177 p. (In Russ.).
5.Vereshchako G.G., Chuyeshova N.V., Tsukanova Ye.V., Bakshayeva M.A. Radiation Damage to Spermatogenic Cells and Epididymal Spermatozoa of Wistar Rats after External Irradiation. Izvestiya Natsional’noy Akademii Nauk Belarusi. Seriya Biologicheskikh Nauk = Bulletin of the National Academy of Sciences of Belarus. Series of Biological Sciences. 2017;2:40-45 (In Russ.).
6.Alahmar A.T. Role of Oxidative Stress in Male Infertility. J. Hum Reprod. Sci. 2019;12;1:4-18. PMID: 31007461. doi: 10.4103/jhrs.JHRS_150_18.
7.Bansal A., Bilaspuri G.S. Impacts of Oxidative Stress and Antioxidants on Semen Functions. Veterinary Medicine International. 2011. Article ID 686137. 7 p. doi: 10.4061/2011/686137.
8.Rozhdestvenskiy L.M. Current Issues of Search and Research of Radiation Protection Agents. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2013;53;5:513-520 (In Russ.). doi: 10.7868/S0869803113050135.
9. Vasin M.V. Classification of Radiation Protection Agents as a Reflection of the Current State and Prospects for the Development of Radiation Pharmacology. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2013;53;5:459-467 (In Russ.). doi: 10.7868/S0869803113050135.
10. Shevchenko V.A., Pomerantseva M.D. Geneticheskiye Posledstviya Deystviya Ioniziruyushchikh Izlucheniy = Genetic Consequences of Ionizing Radiation. Moscow, Nauka Publ., 1985. 279 p. (In Russ.).
11. Filimonova M.V., Makarchuk V.M., Filimonov A.S.,Chesnokova Ye.A, Shevchenko L.I., et al. Radioprotective Effects of Combined Use of the No-Synthase Inhibitor T1023 and Mexamine. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2018;58;6:597-607 (In Russ.). doi: 10.1134/S0869803118050065.
12. Vasin M.V., Ushakov I.B., Chernov Yu.N., Semenova L.A., Afanas’yev R.V. Radiation Protection Properties of Indralin and Essentiale N with Separate and Combined Use Under Conditions of Fractional γ-Irradiation. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2021;61;6:645-651 (In Russ.).
13. Legeza V.I., Grebenyuk A.N., Zargarova N.I. On the Effectiveness of Using Radioprotectors of Different Mechanisms of Action in Lesions Typical of Radiation Accidents (Experimental Study). Mediko-Biologicheskiye i Sotsial’no-Psikhologicheskiye Problemy Bezopasnosti v Chrezvychaynykh Situatsiyakh = Medical, Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2013;1:42-47 (In Russ.).
14. Gudkov C.V., Popova N.P., Bruskov V.I. Radioprotective Substances: History, Trends and Prospects. Biofizika = Biophysics. 2015;60;4:801-811 (In Russ.). doi: 10.1134/S00063509.50401.20.
15. Kuptsova P.S., Zhurakovskaya G.P., Belkina S.V. Features of the Manifestation of the Modifying Properties of Radioprotectors under the Action of Radiation of Different Quality on Eukaryotic Cells. Radiatsiya i Risk = Radiation and Risk. 2021;30;4:52-60 (In Russ.). doi: 10.21870/0131-3878-2021-30-4-52-60.
16. Huang Z., Peng R., Yu H., Chen Z., Wang S., Wang Z., et al.Dimethyl Sulfoxide Attenuates Radiation-Induced Testicular Injury through Facilitating DNA Double-Strand BreakRepair. Oxid Med Cell Longev. 2022. Article ID 9137812. 14 p. doi: 10.1155/2022/9137812/. PMID: 35770047.
17. US Environmental Protection Agency. Robust Summaries and Test Plans: Dimethyl Sulfoxide. Washington, 2026. 19 p.
18. Smith E.R., Hadidian Z., Mason M.M. The Single- and Repeated-Dose Toxicity of Dimethyl Sulfoxide. Ann NY Acad Sci. 1967;141;1:96-109.
19. Wong Linda K., Reinertson Eric L. Clinical Considerations of Dimethyl Sulfoxide. Iowa State University Veterinarian. 1984;46;2:89-95.
20. McKim A.S., Strub R. Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices. Pharm Tech. 2008;32;5:1–8.
21. Ashwood-Smith M. Inability of Dimethyl Sulphoxide to Protect Mouse Testis against the Effect of X-Radiation. Intern. J.Rad.Biol. 1961;3:101-103.
22. Mamina V.P. The Effect of Dimethyl Sulfoxide (DMSO), as Well as the DMSO-Merkamine Combination on Quantitative and Morphological Changes in Spermatozoa Irradiated at Different Stages of Spermatogenesis. VINITI. 1975;72:731-75 (In Russ.).
23. Kudryashov Yu.B. Chemical Protection against Radiation Damage. Sorovskiy Obrazovatel’nyy Zhurnal = Sorov Educational Journal. 2000;6;6:21-26 (In Russ.).
24. Lina Lu, Zongli Li, Yanhua Zuo, Libo Zhao, Bin Liu. Radioprotective Activity of Glutathione on Cognitive Ability in X-ray Radiated Tumor-Bearing Mice. Neurol Res. 2018;40;9:758-766. doi: 10.1080/01616412.2018.1476080.
25. Mamina V.P., Semenov D.I. Method for Determining the Number of Spermatogenic Cells of the Testis in a Cell Suspension. Tsitologiya = Tsitology. 1976;18;7:913-914 (In Russ.).
26. Mamina V.P. The Content of Cyclic Nucleotides in Testicular Tissue in Mice Depending on the Dose of Ionizing Radiation. Deystviye Malykh Doz Ioniziruyushchikh Izlucheniy na Gonady i Plod = Effect of Low Doses of Ionizing Radiation on the Gonads and Fetus. Collection of Reports of the All-Union Conference. Obninsk, October 22-26, 1988. Obninsk, NIIMR AMN SSSR Publ., 1988. P. 44-45 (In Russ.).
27. Molnar Ye. Obshchaya Spermatologiya = General Spermatology. Ed. I.M.Porudominskiy. Budapest, Akademiya nauk Vengrii Publ., 1969. 294 p. (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study was carried out within the framework of state budget financing (No. 122 021000085-1).
Contribution. The article was prepared with the sole participation of the author.
Article received: 20.02.2025. Accepted for publication: 25.03.2025.